Nelson Chao, MD, MBA
Nelson Chao, MD, MBA, is a Professor of Medicine, Professor in Immunology, Research Professor of Global Health, Professor in Pathology, and Affiliate of the Duke Regeneration Center.
Articles
Academic Perspectives and Key Considerations for Optimal Patient Care in cGVHD
May 5th 2025A panelist discusses how successful management of chronic graft-vs-host disease (cGVHD) requires a multifaceted approach that combines prompt recognition, strategic intervention, and comprehensive supportive care to optimize both disease control and quality of life for transplant survivors.
The Treatment Landscape for cGVHD: From Current Practices to Evolving Therapies
April 28th 2025A panelist discusses how the treatment landscape for chronic graft-vs-host disease (cGVHD) has evolved significantly in recent years, with several pivotal clinical trials beyond REACH3 informing our approach, including the REACH1 and REACH2 trials for acute GVHD; the ROCKstar trial supporting belumosudil approval; and studies evaluating ibrutinib, axatilimab, and extracorporeal photopheresis.
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
April 21st 2025A panelist discusses how managing adverse events (AEs) in patients with chronic graft-vs-host disease (cGVHD) treated with ruxolitinib requires a structured monitoring approach that balances therapeutic efficacy with patient safety through regular clinical evaluations, laboratory assessments, and proactive management strategies tailored to individual risk profiles.
Long-Term Outcomes of Ruxolitinib Therapy in Patients With cGVHD
April 14th 2025A panelist discusses how identifying steroid-dependent or steroid-refractory (SR) graft-vs-host disease (GVHD) requires careful clinical monitoring, with the determination typically made when patients show disease progression during prednisone taper, inadequate response after 5 to 7 days of treatment, or persistent disease despite 2 weeks of appropriate steroid therapy.
Current Practices and Initial Treatment Considerations for Patients With cGVHD
April 7th 2025A panelist discusses how steroid therapy remains the cornerstone of acute graft-vs-host disease (GVHD) treatment, with treatment protocols typically starting with prednisone at doses ranging from 1 to 2 mg/kg/day depending on disease severity, though optimal dosing strategies continue to be refined through clinical research.
Clinical Case – A Patient With Steroid-Refractory cGVHD
March 31st 2025A panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting multiple organ systems, including the skin (rash, itching), gastrointestinal tract (diarrhea, nausea, abdominal pain), liver (elevated enzymes, jaundice), and lungs (shortness of breath, cough), with severity assessment typically following established criteria.
